Re: Not even on the radar in this "state of the art" review

...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Reply New Message

Prev Message Back To Forum Threaded View Next Message

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Not even on the radar in this "state of the art" review

in response to

Re: Not even on the radar in this "state of the art" review

BearDownAZ

posted on Jun 20, 2018 03:07PM

"But do Epigentics, and/or BET Inhibition in general and Apabetalone in particluar target "Cardiometabolic Risk"?"

The American Diabetes Association definitely thinks that Type 2 Diabetes and Cardiovascular Disease have something to do with cardiometabolic risk. BETonMACE is being tested in high-risk Type 2 Diabetes subjects with cardiovascular disease.

https://professional.diabetes.org/sites/professional.diabetes.org/files/media/cardiometabolicrisk2015.pdf

5 Recommendations

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Please to post a reply